Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa

This study has been completed.

First Received on October 3, 2005. Last Updated on October 11, 2006 History of Changes

Sponsor:	Institute of Child Health
Information provided by:	Institute of Child Health
ClinicalTrials.gov Identifier:	NCT00231517

Purpose

Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa

Condition	Intervention	Phase
Epidermylosis Bullosa	Drug: topical opiod Drug: morphine sulphate in intrasite gel	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: epidermolysis bullosa simplex epidermolysis bullosa with pyloric atresia junctional epidermolysis bullosa

U.S. FDA Resources

Further study details as provided by Institute of Child Health:

Eligibility

Ages Eligible for Study:	4 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

children under 18 years epidermolysis wounds requiring dressing changes

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00231517

Locations

United Kingdom
Great Ormond Street Hospital and the Institute of Child health
London, United Kingdom, WC1N 1EH

Sponsors and Collaborators

Institute of Child Health

Investigators

Principal Investigator:

Richard Howard, Prof

Institute of Child Health

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00231517 History of Changes
Other Study ID Numbers:	01MH17
Study First Received:	October 3, 2005
Last Updated:	October 11, 2006
Health Authority:	United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:

Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Morphine
Analgesics, Opioid

Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on February 09, 2012